Abstract
Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Current Psychopharmacology
Title: Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Volume: 1
Author(s): Michel Bourin and Martine Hascoet
Affiliation:
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Abstract: Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Export Options
About this article
Cite this article as:
Bourin Michel and Hascoet Martine, Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010002
DOI https://dx.doi.org/10.2174/2211556011201010002 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design Simple and Fast Gas-chromatography Mass Spectrometry Assay to Assess Delta 9-Tetrahydrocannabinol and Cannabidiol in Dogs Treated with Medical Cannabis for Canine Epilepsy
Current Pharmaceutical Biotechnology Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Current Drug Targets Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued) O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results
Current Radiopharmaceuticals Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Anticonvulsant Activity of New GABA Prodrugs
Medicinal Chemistry A Novel Efficient Machine Learning Approach for Multiclass Classification of EEG Signal
Recent Patents on Computer Science Personalized Treatment of Obsessive-Compulsive Disorder: Radiology, EEG, Pharmacogenetics and Biochemistry
Current Pharmacogenomics and Personalized Medicine Maternal Exposure to Quetiapine: Effects on Structural Changes in Developing Brain and its Lasting Impact on Neurobehavioral Impairments in Rat Offspring
Current Psychopharmacology New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets A Multi-Functional Organelle Mitochondrion is Involved in Cell Death, Proliferation and Disease
Current Medicinal Chemistry Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Magnolia officinalis Reduces Inflammation and Damage Induced by Recurrent Status Epilepticus in Immature Rats
Current Pharmaceutical Design Synthesis of Thieno[2,3-d]oxazines and Thieno[2,3-d]thiazines as Subtype Specific Kainate Receptor Antagonists
Current Medicinal Chemistry Marijuana Use in Young Adults: What Do We Know?
Current Psychopharmacology